Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | completed | Phase 1 | 12 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00796731 | SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 77 | SanofiINDUSTRY | 1 | Jul 17, 2012 | clinicaltrials |
| NCT00415064 |
| Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma |
| completed |
| Phase 1 |
| 32 |
| AEterna ZentarisINDUSTRY |
| 1 |
| Jul 6, 2012 |
| clinicaltrials |
| NCT00660166 | Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | completed | Phase 1 | 13 | Tufts Medical CenterOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT01295593 | Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) | unknown | Phase 1 / Phase 2 | 33 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT01010243 | Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial(MM03) | unknown | Phase 1 / Phase 2 | 54 | University of RegensburgOTHER | 1 | May 30, 2012 | clinicaltrials |
| NCT00234169 | A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 10, 2012 | clinicaltrials |
| NCT01098188 | LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia | completed | Phase 1 | 33 | Laboratoire français de Fractionnement et de BiotechnologiesINDUSTRY | 1 | Apr 30, 2012 | clinicaltrials |
| NCT00741871 | A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | completed | Phase 1 | 35 | S*BIOINDUSTRY | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00089453 | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | completed | Phase 1 | 10 | University of ArkansasOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 23, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00388999 | Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant | completed | Phase 1 | 46 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT00281476 | The Effect of High Dose Simvastatine on Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Vejle HospitalOTHER | 0 | Nov 1, 2011 | clinicaltrials |
| NCT00036257 | Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 15 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | completed | Phase 1 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 28, 2011 | clinicaltrials |
| NCT01221103 | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | unknown | Phase 1 / Phase 2 | 50 | Southern Europe New Drug OrganizationOTHER | 1 | Sep 13, 2011 | clinicaltrials |
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 50 | University of LeipzigOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | completed | Phase 1 | 72 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Aug 4, 2011 | clinicaltrials |
| NCT00880867 | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | terminated | Phase 1 | 3 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00768339 | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | terminated | Phase 1 / Phase 2 | 25 | Aegera TherapeuticsINDUSTRY | 2 | Jul 13, 2011 | clinicaltrials |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | unknown | Phase 1 | 55 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01199718 | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 22 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00752518 | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 35 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00621400 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Nantes University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT01322776 | Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2011 | clinicaltrials |
| NCT01296204 | Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131(BB4) | completed | Phase 1 | 33 | Centre René GauducheauOTHER | 1 | Mar 22, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00285103 | SPC2996 in Chronic Lymphocytic Leukaemia | completed | Phase 1 / Phase 2 | 46 | Santaris Pharma A/SINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | completed | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT00271050 | External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 12 | The Cleveland ClinicOTHER | 1 | Dec 21, 2010 | clinicaltrials |
| NCT01021358 | A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). | completed | Phase 1 | 12 | AbbottINDUSTRY | 1 | Dec 20, 2010 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT01233895 | Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma | completed | Phase 1 | 26 | SanofiINDUSTRY | 2 | Nov 3, 2010 | clinicaltrials |
| NCT00935597 | Host Dendritic Cells in Allograft Patients | unknown | Phase 1 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 29, 2010 | clinicaltrials |
| NCT00689000 | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 57 | Chroma TherapeuticsINDUSTRY | 1 | Oct 22, 2010 | clinicaltrials |
| NCT00743028 | Assess the Oral Bioavailability of New ABT-263 Formulations | completed | Phase 1 | 36 | AbbottINDUSTRY | 1 | Oct 7, 2010 | clinicaltrials |
| NCT00083460 | Study of Combination PS-341 and Thalidomide in Multiple Myeloma | completed | Phase 1 | 86 | University of ArkansasOTHER | 1 | Aug 2, 2010 | clinicaltrials |
| NCT00081757 | An Open Protocol for the Compassionate Use of Thalidomide | completed | Phase 1 / Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00868478 | The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 1 / Phase 2 | 15 | Kaplan Medical CenterOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00646165 | Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Mundipharma Research LimitedINDUSTRY | 1 | Mar 31, 2010 | clinicaltrials |
| NCT00319930 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | terminated | Phase 1 | 10 | BiogenINDUSTRY | 1 | Mar 8, 2010 | clinicaltrials |
| NCT00459069 | The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma | completed | Phase 1 | 18 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 12, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jul 19, 2012source: clinicaltrials